1Department of Health Sciences and Pediatric Dentistry, Piracicaba Dental School, State University of Campinas (Unicamp), São Paulo, Brazil
2Anhembi Morumbi University, Piracicaba / São Paulo, Brazil
3Postgraduate Program in Movement Sciences and Administration, Methodist University of Piracicaba, Piracicaba / São Paulo, Brazil
4Department of Health Sciences and Pediatric Dentistry, Piracicaba Dental School, State University of Campinas (Unicamp), Piracicaba / São Paulo, Brazil
©2024 Jaseng Medical Foundation
This is an open access article under the CC BY-NC license (http://creativecommons.org/licenses/by-nc/4.0/).
Authors Contributions
Conceptualization: BSB and MLRS. Methodology: BSB and MLRS. Formal investigation: BSB and MLRS. Data analysis: MILM. Writing original draft: BSB and TBA. Writing - review and editing: TBA and MLRS.
Conflicts of Interest
There are no conflicts of interest associated with this publication.
Funding
The study was financed by the São Paulo State Research Support Foundation - “Fundação de Amparo à Pesquisa do Estado de São Paulo” (FAPESP) - Process Number: 2020/06875-2.
Ethical Statement
This study was approved by the Research Ethics Committee of the Piracicaba Dental School (CAAE: 34463820.0.0000.5418) and the Brazilian Clinical Trials Registry - REBEC (no.: RBR-96bkkj7).
Variables | Test group (n = 24) | Placebo group (n = 24) | CI (95%), p* |
---|---|---|---|
Age (y) | 41.46 ± 13.08 | 33.71 ± 14.2 | −0.19–15.69, 0.055 |
|
|||
Sex, n (%) | 0.683 | ||
Female | 21 (87.5) | 20 (83.3) | |
Male | 3 (12.5) | 4 (16.7) | |
|
|||
Initial† VAS score | 6.96 ± 1.75 | 6.21 ± 0.36 | −0.27–1.77, 0.145 |
|
|||
Initial† algometry measurement (kgf/cm2) | |||
GB20 right | 2.56 ± 0.87 | 1.92 ± 0.79 | 0,16–1.13, 0.010 |
GB20 left | 2.53 ± 0.69 | 2.66 ± 0.85 | −0.58–0.33, 0.574 |
GB21 right | 4.07 ± 1.43 | 3.60 ± 1.43 | −0.36–1.30, 0.261 |
GB21 left | 4.25 ± 1.59 | 3.09 ± 1.34 | 0.30–2.01, 0.009 |
General energy (mA) | 19.63 ± 9.86 | 18.83 ± 12.18 | −5.65–7.23, 0.806 |
Test group (average VAS scores ± SD) | Placebo group (average VAS scores ± SD) | CI (95%), p | |
---|---|---|---|
Initial* | 6.96 ± 1.75 | 6.21 ± 1.75 | −0.27–1.77, 0.145 |
Final† | 4.25 ± 2.54 | 5.21 ± 2.54 | −2.43–0.52, 0.197 |
Late‡ | 3.50 ± 2.87 | 5.50 ± 2.87 | −3.67- -0.33, 0.020 |
Algometry measurement (kgf/cm2) | Before intervention | After intervention | ||||
---|---|---|---|---|---|---|
|
|
|||||
Test group | Placebo group | CI (95%), p* | Test group | Placebo group | CI (95%), p* | |
GB20 right | 2,564 | 1,918 | 0.16–1.13, 0.010 | 2,636 | 1,898 | 0.18–1.30, 0.011 |
|
||||||
GB20 left | 2,529 | 2,656 | −0.58–0.33, 0.574 | 2,491 | 1,948 | 0.09–0.99, 0.019 |
|
||||||
GB21 right | 4,075 | 3,604 | −0.36–1.30, 0.261 | 4,214 | 3,418 | −0.21–1.80, 0.117 |
|
||||||
GB21 left | 4,246 | 3,091 | 0.30–2.01, 0.009 | 4,126 | 3,533 | −0.27–1.46, 0.175 |
Test group | Placebo group | |||||
---|---|---|---|---|---|---|
|
|
|||||
Before application of electromagnetism | After application of electromagnetism | CI (95%), p* | Before application of electromagnetism | After application of electromagnetism | CI (95%), p* | |
General energy (μA) | 19.62 | 13.50 | 3.10–9.15, < 0.001 | 18.83 | 15.04 | 0.76–6.82, 0.015 |
|
||||||
Meridian energy (μA) | ||||||
Lung | 22.73 | 15.33 | 1.74–13.05, 0.012 | 25.21 | 16.94 | 2.61–13.93, 0.005 |
|
||||||
Pericardium | 19.58 | 10.15 | 4.46–14.41, < 0.001 | 19.48 | 13.30 | 1.21–11.61, 0.016 |
|
||||||
Heart | 19.35 | 11.31 | 4.29–11.80, < 0.001 | 18.33 | 12.80 | 1.79–9.30, 0.005 |
|
||||||
Small intestine | 21.83 | 14.43 | 2.10–12.69, 0.007 | 23.19 | 17.83 | 0.06–10.65, 0.047 |
|
||||||
Triple heater | 29.73 | 24.95 | 0.33–9.21, 0.036 | 27.17 | 24.12 | −1.40–7.48, 0.174 |
|
||||||
Large intestine | 30.06 | 20.75 | 3.71–14.92, 0.002 | 29.81 | 26.54 | −2.33–8.88, 0.246 |
|
||||||
Spleen-pancreas | 17.71 | 13.16 | 0.91–8.17, 0.015 | 17.23 | 16.54 | −2.95–4.32, 0.705 |
|
||||||
Liver | 18.21 | 13.08 | 0.90–9.35, 0.018 | 16.83 | 12.10 | 0.50–8.95, 0.029 |
|
||||||
Kidney | 19.56 | 15.20 | −0.20–8.91, 0.061 | 18.29 | 14.44 | −0.70–8.41, 0.095 |
|
||||||
Bladder | 11.43 | 8.10 | 0.56–6.11, 0.020 | 12.23 | 11.37 | −1.92–3.63, 0.538 |
|
||||||
Gallbladder | 11.79 | 8.10 | 1.63–5.75, 0.001 | 10.41 | 8.18 | 0.17–4.29, 0.035 |
|
||||||
Stomach | 18.83 | 13.91 | 0.96–8.87, 0.016 | 14.16 | 11.29 | −1.08–6.83, 0.150 |
Acupuncture point | Power | Location | Duration (min) |
---|---|---|---|
KI1 | Earth | Sole of the foot | 10 |
GV4 | Depression beneath the spinous process of L2 | 5 | |
GV20 | Heaven | Top of the head | 3 |
Area with pain | The area varies with each patient | 10 |
Variables | Test group (n = 24) | Placebo group (n = 24) | CI (95%), p |
---|---|---|---|
Age (y) | 41.46 ± 13.08 | 33.71 ± 14.2 | −0.19–15.69, 0.055 |
| |||
Sex, n (%) | 0.683 | ||
Female | 21 (87.5) | 20 (83.3) | |
Male | 3 (12.5) | 4 (16.7) | |
| |||
Initial |
6.96 ± 1.75 | 6.21 ± 0.36 | −0.27–1.77, 0.145 |
| |||
Initial | |||
GB20 right | 2.56 ± 0.87 | 1.92 ± 0.79 | 0,16–1.13, 0.010 |
GB20 left | 2.53 ± 0.69 | 2.66 ± 0.85 | −0.58–0.33, 0.574 |
GB21 right | 4.07 ± 1.43 | 3.60 ± 1.43 | −0.36–1.30, 0.261 |
GB21 left | 4.25 ± 1.59 | 3.09 ± 1.34 | 0.30–2.01, 0.009 |
General energy (mA) | 19.63 ± 9.86 | 18.83 ± 12.18 | −5.65–7.23, 0.806 |
Test group (average VAS scores ± SD) | Placebo group (average VAS scores ± SD) | CI (95%), p | |
---|---|---|---|
Initial |
6.96 ± 1.75 | 6.21 ± 1.75 | −0.27–1.77, 0.145 |
Final |
4.25 ± 2.54 | 5.21 ± 2.54 | −2.43–0.52, 0.197 |
Late |
3.50 ± 2.87 | 5.50 ± 2.87 | −3.67- -0.33, 0.020 |
Algometry measurement (kgf/cm2) | Before intervention | After intervention | ||||
---|---|---|---|---|---|---|
|
| |||||
Test group | Placebo group | CI (95%), p |
Test group | Placebo group | CI (95%), p | |
GB20 right | 2,564 | 1,918 | 0.16–1.13, 0.010 | 2,636 | 1,898 | 0.18–1.30, 0.011 |
| ||||||
GB20 left | 2,529 | 2,656 | −0.58–0.33, 0.574 | 2,491 | 1,948 | 0.09–0.99, 0.019 |
| ||||||
GB21 right | 4,075 | 3,604 | −0.36–1.30, 0.261 | 4,214 | 3,418 | −0.21–1.80, 0.117 |
| ||||||
GB21 left | 4,246 | 3,091 | 0.30–2.01, 0.009 | 4,126 | 3,533 | −0.27–1.46, 0.175 |
Test group | Placebo group | |||||
---|---|---|---|---|---|---|
|
| |||||
Before application of electromagnetism | After application of electromagnetism | CI (95%), p |
Before application of electromagnetism | After application of electromagnetism | CI (95%), p | |
General energy (μA) | 19.62 | 13.50 | 3.10–9.15, < 0.001 | 18.83 | 15.04 | 0.76–6.82, 0.015 |
| ||||||
Meridian energy (μA) | ||||||
Lung | 22.73 | 15.33 | 1.74–13.05, 0.012 | 25.21 | 16.94 | 2.61–13.93, 0.005 |
| ||||||
Pericardium | 19.58 | 10.15 | 4.46–14.41, < 0.001 | 19.48 | 13.30 | 1.21–11.61, 0.016 |
| ||||||
Heart | 19.35 | 11.31 | 4.29–11.80, < 0.001 | 18.33 | 12.80 | 1.79–9.30, 0.005 |
| ||||||
Small intestine | 21.83 | 14.43 | 2.10–12.69, 0.007 | 23.19 | 17.83 | 0.06–10.65, 0.047 |
| ||||||
Triple heater | 29.73 | 24.95 | 0.33–9.21, 0.036 | 27.17 | 24.12 | −1.40–7.48, 0.174 |
| ||||||
Large intestine | 30.06 | 20.75 | 3.71–14.92, 0.002 | 29.81 | 26.54 | −2.33–8.88, 0.246 |
| ||||||
Spleen-pancreas | 17.71 | 13.16 | 0.91–8.17, 0.015 | 17.23 | 16.54 | −2.95–4.32, 0.705 |
| ||||||
Liver | 18.21 | 13.08 | 0.90–9.35, 0.018 | 16.83 | 12.10 | 0.50–8.95, 0.029 |
| ||||||
Kidney | 19.56 | 15.20 | −0.20–8.91, 0.061 | 18.29 | 14.44 | −0.70–8.41, 0.095 |
| ||||||
Bladder | 11.43 | 8.10 | 0.56–6.11, 0.020 | 12.23 | 11.37 | −1.92–3.63, 0.538 |
| ||||||
Gallbladder | 11.79 | 8.10 | 1.63–5.75, 0.001 | 10.41 | 8.18 | 0.17–4.29, 0.035 |
| ||||||
Stomach | 18.83 | 13.91 | 0.96–8.87, 0.016 | 14.16 | 11.29 | −1.08–6.83, 0.150 |
The Initial (before the start of the protocol). CI (95%) = 95% confidence interval; VAS = visual analogue scale.
Initial (before the start of the protocol). Final (immediately after removing the device). Late (the day after the session had been conducted). CI (95%) = 95% confidence interval; VAS = visual analogue scale.
The analysis of variance with Bonferroni correction was set with a significance level of CI (95%) = 95% confidence interval.
The CI (95%) = 95% confidence interval.